Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.

ABSTRACT: Immunotherapy is being tested intensively in clinical trials for prostate cancer; it includes immune checkpoint inhibition, prostate specific antigen (PSA) vaccines and dendritic cell-based strategies. Despite increasing evidence for clinical responses, the consensus of multiple trials is that prostate cancers are poorly responsive to immunotherapy. Prostate cancer has a high degree of pathological and genetic heterogeneity compared to other cancer types, which may account for immunotherapeutic resistance. This hypothesis also implies that select types of prostate tumors may be differentially responsive to immune-based strategies and that the clinical stage, pathological grade and underlying genetic landscape may be important criteria in identifying tumors that respond to immune therapies.

SUBMITTER: Bryant G 

PROVIDER: S-EPMC5536030 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature